
Stepan Company: Upside Unclear, Better Alternatives Exist
Stepan Company remains a 'BUY' with a lowered fair value estimate of $85/share and a price target of $71/share, reflecting increased market uncertainty. SCL's 2025 results show early signs of operational recovery—6% EBITDA growth, reduced net debt, and positive FCF in 4Q25—driven by asset rationalization and cost savings. 2026E forecasts nearly double AEPS versus 2025, with 47% growth expected, but much of this upside appears priced in after the recent share price surge.


















